Dr. Reddy's Laboratories Ltd. (RDY) Stock Price, Financials & Summary

Price chart

Sep 22Sep 25Sep 30Oct 5Oct 8Oct 13Oct 16Oct 21

Key dataOct 21, 2026

Open$13.24

From 52W high−14.24%

Volume2.11M

Market cap$10.99B

P/E (TTM)31.4x

P/S (TTM)3.1x

Div yield1.12%

Key dataOct 21, 2026

Open

$13.24

From 52W high

−14.24%

Volume

2.11M

Market cap

$10.99B

ValuationView details →

P/E (Fwd)

34.6x

EV/EBITDA

16.9x

P/E (TTM)

31.4x

RSI (14)

65.0

MomentumView details →

1D Return

−0.53%

YTD Return

−6.16%

SummaryUpdated Jun 1, 2026

Dr. Reddy's Laboratories Limited (NYSE:RDY) is an Indian multinational pharmaceutical company founded in 1984 and headquartered in Hyderabad, India. The company has evolved from a small startup into one of India's largest pharmaceutical companies, going public on the New York Stock Exchange in 2001. Dr. Reddy's operates as an integrated pharmaceutical company with a global presence, manufacturing and marketing generic drugs, active pharmaceutical ingredients, and developing proprietary products across multiple therapeutic areas including cardiovascular, gastrointestinal, oncology, and diabetes treatments.

Ask drillr about Dr. Reddy's Laboratories Ltd. →

ValuationView details →

P/E (Fwd)

34.6x

P/E (TTM)

31.4x

EV/EBITDA

16.9x

EV/Sales

3.1x

P/S (TTM)

3.1x

P/B (TTM)

2.7x

ProfitabilityView details →

Gross Margin

50.15%

Net Margin

9.96%

EBITDA Margin

18.37%

ROE (TTM)

8.65%

ROA (TTM)

5.77%

Asset Turnover

0.58x

GrowthView details →

Revenue YoY

−0.43%

EPS YoY

−41.59%

FCF YoY

+4.89%

Revenue CAGR 3Y

+12.86%

EPS CAGR 3Y

−0.23%

EBITDA YoY

−37.67%

MomentumView details →

1D Return

−0.53%

YTD Return

−6.16%

1Y Return

−11.40%

RSI (14)

65.0

vs 50D SMA

+6.91%

vs 200D SMA

−0.22%

Capital & dividendView details →

Debt/Equity

0.19x

Current Ratio

1.90x

Quick Ratio

1.39x

Div Yield

1.12%

Div Rate

$0.15

Div Growth 1Y

+61.36%

EarningsView details →

EPS (Actual)

$0.06

EPS Surprise

−34.65%

Beats (12Q)

6/12

Next Q EPS Est

$0.12

Avg Surprise (4Q)

−15.61%

Rev Surprise

−1.75%

Financials snapshotView financials →

Revenue (TTM)

332.83B

Net Income (TTM)

33.17B

Op. CF (TTM)

40.99B

Next earningsOct 23, 2026 →

Latest newsMore news →

India’s Food Safety and Standards Authority issued a notice to the DR REDDYS LABORATORIES LTD over allegedly misleading and ambiguous claims about its GLP-1 supplement.14d ago

Takeda's QDENGA, a live-attenuated tetravalent dengue vaccine, is set to become India's first approved dengue vaccine, with private-market availability expected in the first half of 2027.34d ago

Similar companies

羚锐制药600285.SH Fujian Haixi Pharmaceuticals Co., Ltd.02637.HK Elanco Animal Health IncorporatedELAN 康恩贝600572.SH 国药现代600420.SH 微芯生物688321.SH Find similar companies →

Latest newsMore news →

India’s Food Safety and Standards Authority issued a notice to the DR REDDYS LABORATORIES LTD over allegedly misleading and ambiguous claims about its GLP-1 supplement.14d ago Takeda's QDENGA, a live-attenuated tetravalent dengue vaccine, is set to become India's first approved dengue vaccine, with private-market availability expected in the first half of 2027.34d ago Dr Reddy's Laboratories signed a distribution agreement with Takeda Pharmaceutical Company for the promotion and distribution of the Qdenga dengue vaccine in India.34d ago